1. Recurrent PTPRB and PLCG1 mutations in angiosarcoma
- Author
-
Adrienne M. Flanagan, Sahil Seth, Jiabin Tang, Michael R. Stratton, Sancha Martin, Matilda Katan, Alexander J. Lazar, Ultan McDermott, Manasa Ramakrishna, Gunes Gundem, Yu Cao, Graham Steers, Laura Mudie, Inigo Martincorena, P. Andrew Futreal, Adam Butler, Sam Behjati, Helen Sheldon, Jon W. Teague, Xingzhi Song, Vinod Ravi, Chris Boshoff, Ioannis Roxanis, Peter Van Loo, Peter J. Campbell, Susanna L. Cooke, Jianhua Zhang, Davis R. Ingram, Keila E. Torres, Tom D. Bunney, Ghadah A. Al Sannaa, Alexei Protopopov, Hans Koss, Daniel Baumhoer, M Fernanda Amary, Olivia Joseph, Hans Kristian Moen Vollan, Curtis Gumbs, Latasha Little, Bhavisha Khatri, Nischalan Pillay, Adrian L. Harris, Harshad S. Mahadeshwar, Roberto Tirabosco, Claire Hardy, Dina Halai, Patrick S. Tarpey, M Patil, David C. Wedge, and Elli Papaemmanuil
- Subjects
Vascular Endothelial Growth Factor A ,Angiogenesis ,Hemangiosarcoma ,Molecular Sequence Data ,Biology ,medicine.disease_cause ,Article ,PTPRB ,Neovascularization ,Human Umbilical Vein Endothelial Cells ,Genetics ,medicine ,Humans ,Missense mutation ,Exome ,Angiosarcoma ,Analysis of Variance ,Mutation ,Base Sequence ,Neovascularization, Pathologic ,Phospholipase C gamma ,Sequence Analysis, RNA ,Receptor-Like Protein Tyrosine Phosphatases, Class 3 ,Vascular endothelial growth factor A ,Cancer research ,RNA Interference ,medicine.symptom ,Tyrosine kinase - Abstract
Angiosarcoma is an aggressive malignancy that arises spontaneously or secondarily to ionizing radiation or chronic lymphoedema. Previous work has identified aberrant angiogenesis, including occasional somatic mutations in angiogenesis signaling genes, as a key driver of angiosarcoma. Here we employed whole-genome, whole-exome and targeted sequencing to study the somatic changes underpinning primary and secondary angiosarcoma. We identified recurrent mutations in two genes, PTPRB and PLCG1, which are intimately linked to angiogenesis. The endothelial phosphatase PTPRB, a negative regulator of vascular growth factor tyrosine kinases, harbored predominantly truncating mutations in 10 of 39 tumors (26%). PLCG1, a signal transducer of tyrosine kinases, encoded a recurrent, likely activating p.Arg707Gln missense variant in 3 of 34 cases (9%). Overall, 15 of 39 tumors (38%) harbored at least one driver mutation in angiogenesis signaling genes. Our findings inform and reinforce current therapeutic efforts to target angiogenesis signaling in angiosarcoma.
- Published
- 2014
- Full Text
- View/download PDF